Edwards Lifesciences says PASCAL tricuspid repair system meets main goal in CLASP II TR study
EW•Edwards Lifesciences said its PASCAL system demonstrated superior clinical and quality-of-life benefits in the CLASP II TR trial; 80% of PASCAL patients achieved no more than moderate tricuspid regurgitation at one year, versus 30% of controls.
1. Trial results
Edwards Lifesciences said the PASCAL system demonstrated superiority in the CLASP II TR trial at six months. At one year, 80% of PASCAL patients achieved no more than moderate tricuspid regurgitation, compared with 30% of controls.
